Response Biomedical Corp. Announces Receipt of Fifth Milestone in Co-Development Collaboration

December 30, 2015

December 30, 2015 – Response Biomedical Corp. VANCOUVER, B.C., December 30, 2015 – Response Biomedical Corp. (“Response” or “the Company”) (TSX: RBM, OTCQB: RPBIF), has received the fifth milestone of US$720,000 in the Collaboration Agreement with Hangzhou Joinstar Biomedical Technology Co. Ltd. (“Joinstar”). The milestone payment was received upon the receipt of certain testing reports … Continue reading Response Biomedical Corp. Announces Receipt of Fifth Milestone in Co-Development Collaboration

Qu Biologics Closes Oversubscribed Financing

December 23, 2015

December 23, 2015 – Crohn’s Disease Phase 2 Clinical Trial ~ Results in First Quarter 2016 Vancouver, British Columbia – December 23, 2015 -Qu Biologics Inc ., a biotechnology company developing Site Specific Immunomodulators (SSIs) that aim to restore the body’s normal immune response, announced it has closed an oversubscribed private financing of CDN$3.5 million … Continue reading Qu Biologics Closes Oversubscribed Financing

Aquinox Pharmaceuticals Announces Appointment of Ms. Shelley McCloskey as Vice President, Human Resources & Administration

December 22, 2015

December 22, 2015 – Aquinox Pharmaceuticals Inc. VANCOUVER, British Columbia, Dec. 22, 2015 (GLOBE NEWSWIRE) — Aquinox Pharmaceuticals, Inc. (“Aquinox”) (NASDAQ:AQXP), a clinical-stage pharmaceutical company discovering and developing targeted therapeutics in disease areas of inflammation and immuno-oncology, is pleased to announce the appointment of Ms. Shelley McCloskey as Vice President of Human Resources & Administration. … Continue reading Aquinox Pharmaceuticals Announces Appointment of Ms. Shelley McCloskey as Vice President, Human Resources & Administration

Xenon and Genentech Publish in Science the 3-D Crystal Structure of a Novel Nav1.7 Compound Binding Site Enabling the Development of Potent Selective Inhibitors to Treat Pain

December 17, 2015

December 17, 2015 – Xenon Pharmaceuticals Inc. BURNABY, British Columbia, Dec. 17, 2015 (GLOBE NEWSWIRE) — Xenon Pharmaceuticals Inc. (NASDAQ:XENE), a clinical-stage biopharmaceutical company, today announced publication of a key article in Science by researchers at Xenon and Genentech describing for the first time the X-ray crystal structure of a pharmacological binding site on the … Continue reading Xenon and Genentech Publish in Science the 3-D Crystal Structure of a Novel Nav1.7 Compound Binding Site Enabling the Development of Potent Selective Inhibitors to Treat Pain

RepliCel Announces Completion of First Injections in Clinical Trial of RCS-01 for Skin Aging and UV-Damaged Skin

December 17, 2015 – RepliCel Life Sciences Inc Phase 1 clinical trial investigating the use of a patient-specific cell-based dermal rejuvenation product (RCS-01) is scheduled to deliver data in late 2016 VANCOUVER, BC – December 17, 2015 – RepliCel Life Sciences Inc. (OTCQB: REPCF) (TSX.V: RP), a clinical stage regenerative medicine company focused on the … Continue reading RepliCel Announces Completion of First Injections in Clinical Trial of RCS-01 for Skin Aging and UV-Damaged Skin

BioTalent Canada: New Project Helps Canadians with Disabilities Land a Job in Biotechnology

December 16, 2015

December 16, 2015 – BioTalent Canada OTTAWA, December 16, 2015 – A new project, funded in part by the Government of Canada’s Opportunities Fund for Persons with Disabilities (OF) program, has been launched by BioTalent Canada, and will provide over $1 million in wage subsidies over the next three years to assist 90 Canadians with … Continue reading BioTalent Canada: New Project Helps Canadians with Disabilities Land a Job in Biotechnology

Aquinox Selected for Addition to NASDAQ Biotechnology Index

December 16, 2015 – Aquinox Pharmaceuticals, Inc VANCOUVER, British Columbia, Dec. 16, 2015 (GLOBE NEWSWIRE) — Aquinox Pharmaceuticals, Inc. (“Aquinox”) (NASDAQ:AQXP), a clinical-stage pharmaceutical company discovering and developing targeted therapeutics in disease areas of inflammation and immuno-oncology, today announced that it has been selected for addition to the NASDAQ Biotechnology Index effective prior to market … Continue reading Aquinox Selected for Addition to NASDAQ Biotechnology Index

Aquinox to Participate in Two Upcoming Investor Events

December 10, 2015

December 10, 2015 – Aquinox Pharmaceuticals Inc. VANCOUVER, British Columbia, Dec. 10, 2015 (GLOBE NEWSWIRE) — Aquinox Pharmaceuticals, Inc. (“Aquinox”) (NASDAQ:AQXP), a clinical-stage pharmaceutical company discovering and developing targeted therapeutics in disease areas of inflammation and immuno-oncology, today announced that senior management will be meeting with investors at two upcoming investor events. Aquinox also announced … Continue reading Aquinox to Participate in Two Upcoming Investor Events